A new drug is expected to be used to treat diabetic retinal lesions

an international team of researchers has announced the development of a new drug that can be used to treat diabetic retinal lesions, and in mouse trials, promising new options for treating human diabetic retinal lesions.
diabetes retinal lesions are a common complication of diabetes and the main cause of diabetes blindness.According to jennifer Gamble,
's research leader and a professor at the Centennial Institute of Australia, diabetic retinal lesions are mainly caused by damage to the blood-retinal barrier, the integrity of which depends on the tightness of the connections between capillary endoblast cells, which can cause blood to seep out of the retinal capillaries to form lesions if the gap between endoblast cells is too large or damaged.
drug developed by Gamble and others is called CD5-2. Studies have found that the drug repairs the blood-retina barrier and reduces blood vessel leakage. The effectiveness of the drug has been tested in mice and the results are published in the German journal Diabetes.
drug can be used alone or in combination with other existing therapies, promising to better treat diabetic retinal lesions, the researchers said in a statement. They are currently promoting clinical trials. (Source: Xinhua News Agency)